ZYNLONTA shows high response rate in lymphoma trial By Investing.com

Published on 6 May 2024 on Investing.com

ADC Therapeutics SA (NYSE:ADCT) reported promising initial results from a Phase 2 clinical trial of...

Read the rest of the article

Start tracking your investments with Statfolio

Key Insights The projected fair value for ADC Therapeutics is US$1.49 based on 2 Stage Free Cash...

Simply Wall St. · via Yahoo Finance 2 Jan 2025

ADC Therapeutics SA (NYSE:ADCT) is set to release its Q3 2024 earnings on Nov 7, 2024. The consen...

GuruFocus.com · via Yahoo Finance 6 Nov 2024

Key Insights Using the 2 Stage Free Cash Flow to Equity, ADC Therapeutics fair value estimate is ...

Simply Wall St. · via Yahoo Finance 20 Jun 2024

On May 7, 2024, Ameet Mallik, Chief Executive Officer of ADC Therapeutics SA (NYSE:ADCT), sold 29...

GuruFocus.com via Yahoo Finance 10 May 2024

Last week, you might have seen that ADC Therapeutics SA (NYSE:ADCT) released its quarterly result...

Simply Wall St. via Yahoo Finance 9 May 2024

ADC Therapeutics SA (NYSE:ADCT) Q1 2024 Earnings Call Transcript May 6, 2024 ADC Therapeutics SA ...

Insider Monkey via Yahoo Finance 7 May 2024

ADC Therapeutics SA (ADCT) came out with a quarterly loss of $0.56 per share in line with the Zac...

Zacks via Yahoo Finance 6 May 2024

ADC Therapeutics SA (NYSE:ADCT) reported promising initial results from a Phase 2 clinical trial ...

Investing.com 6 May 2024

Investing.com 6 May 2024

There's been a notable change in appetite for ADC Therapeutics SA (NYSE:ADCT) shares in the week ...

Simply Wall St. via Yahoo Finance 16 Mar 2024